Prognostic impact of surgery after chemotherapy for type 4 gastric cancer

Surg Today. 2021 Nov;51(11):1851-1859. doi: 10.1007/s00595-021-02320-7. Epub 2021 Jun 11.

Abstract

Purpose: To assess the clinical indications for, and prognostic impact of surgery after, chemotherapy for type 4 gastric cancer.

Methods: The subjects of this retrospective study were 67 patients who received chemotherapy for type 4 gastric cancer. The patients were grouped into those with progressive disease (PD group) and those without PD (non-PD group), according to the tumor response to chemotherapy.

Results: Distant metastases developed in 58 patients. With regard to tumor response, there were 16 patients in the PD group and 51 patients in the non-PD group. The prognosis of the PD group patients was significantly poorer than that of the non-PD group patients (p < 0.0001). R0 resection was performed for 21 of 23 patients who underwent surgery after chemotherapy. Multivariate analysis revealed tumor response and surgery as independent prognostic factors (p = 0.0001 and p = 0.0009, respectively). Moreover, multivariate analysis of the surgery group revealed that metastatic nodal status (N0-1 vs. N2-3) and residual tumor status (R0 vs. R1-2) were significant independent prognostic factors (p = 0.0258 and p = 0.0458, respectively).

Conclusion: The findings of this study suggest that surgery after chemotherapy for type 4 gastric cancer may improve the prognosis of responders with N0-1 status, who undergo curative R0 resection.

Keywords: Chemotherapy; Gastric cancer; Prognosis; Surgery; Type 4.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Combined Modality Therapy
  • Disease Progression
  • Female
  • Gastrectomy / methods*
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms / classification
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery*

Substances

  • Antineoplastic Agents